Huang Tingting, Debelius Justine W, Ploner Alexander, Xiao Xiling, Zhang Tingting, Hu Kai, Zhang Zhe, Wang Rensheng, Ye Weimin
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China; Radiation Oncology Clinical Medical Research Center of Guangxi, Nanning, Nanning, P. R. China.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):145-150. doi: 10.1016/j.ijrobp.2020.08.054. Epub 2020 Aug 28.
The human commensal microbiome has been suggested to be involved in the regulation of response to anticancer therapies. However, little is known regarding changes in commensal microbes in patients with cancer during radiation therapy. We conducted a prospective, longitudinal proof-of-concept cohort study with patients with newly diagnosed nasopharyngeal carcinoma (NPC) who underwent radiation therapy-based treatment.
Nasopharyngeal swabs were collected before radiation therapy, twice per week during radiation therapy, and after radiation therapy. The nasopharyngeal microbiome was assessed using 16S rRNA amplicon sequencing. A patient's response to treatment was measured 3 months after the completion of radiation therapy as a short-term clinical outcome. In total, 39 NPC patients with 445 nasopharyngeal samples were analyzed.
There was stable temporal change in the community structure of the nasopharyngeal microbiome among patients with NPC during treatment (P = .0005). Among 73 abundant amplicon sequence variants (ASVs), 7 ASVs assigned to genus Corynebacterium decreased significantly during the treatment (W-statistic >80%); 23 ASVs showed statistically significant changes in the ratio of abundance between early and late responders during treatment (false discovery rate <0.05).
This study addressed stable temporal change in the nasopharyngeal microbiome among patients with NPC during radiation therapy-based treatment and provided preliminary evidence of an association with a short-term clinical outcome.
有人提出人类共生微生物群参与了对抗癌治疗反应的调节。然而，对于癌症患者在放射治疗期间共生微生物的变化知之甚少。我们对新诊断的鼻咽癌（NPC）患者进行了一项前瞻性、纵向概念验证队列研究，这些患者接受了以放射治疗为基础的治疗。
在放射治疗前、放射治疗期间每周两次以及放射治疗后采集鼻咽拭子。使用16S rRNA扩增子测序评估鼻咽微生物群。在放射治疗完成后3个月测量患者的治疗反应，作为短期临床结果。总共分析了39例NPC患者的445份鼻咽样本。
NPC患者在治疗期间鼻咽微生物群的群落结构存在稳定的时间变化（P = 0.0005）。在73个丰富的扩增子序列变体（ASV）中，7个属于棒状杆菌属的ASV在治疗期间显著减少（W统计量>80%）；23个ASV在治疗期间早期和晚期反应者之间的丰度比有统计学显著变化（错误发现率<0.05）。
本研究探讨了NPC患者在以放射治疗为基础的治疗期间鼻咽微生物群的稳定时间变化，并提供了与短期临床结果相关的初步证据。
